SPOT-MAS: Advanced Multi-Cancer Early Detection (MCED) via a Single Blood Test

SPOT-MAS (Screening for the Presence Of Tumor by Multi-omics features) is a cutting-edge, proactive cancer screening technology (MCED) designed to detect cancer at its earliest stages, even before symptoms appear. By analysing circulating tumour DNA (ctDNA) released by cancer cells into the bloodstream via a single 10ml blood draw, SPOT-MAS utilises Next-Generation Sequencing (NGS) and AI-driven algorithms to identify 10 types of cancer and predict their organ of origin with high precision.

Why Choose Proactive Cancer Screening with SPOT-MAS?

The Challenge of Late Detection: Cancer remains a leading cause of mortality globally, primarily due to delayed diagnosis when treatment is less effective.
Early Warning Signal: SPOT-MAS acts as a “pre-warning” system, allowing for medical intervention at a stage where survival rates are significantly higher.
Advanced Multi-omics Analysis: Unlike standard tests, SPOT-MAS evaluates DNA across multiple dimensions, including Genetics, Epigenetics (Methylation), and Fragmentomics (DNA fragment size).
AI-Powered Accuracy: Sophisticated Machine Learning models process complex genomic data to ensure reliable results and minimize unnecessary investigations.

Efficacy and Accuracy

SPOT-MAS has been developed and validated through extensive clinical data to provide trustworthy results:

99.8% Specificity: In a group of 1,000 cancer-free individuals, approximately 998 will correctly receive a negative result, significantly reducing the chance of “false positives”.
~78% Sensitivity: A high capability for detecting ctDNA signals compared to other non-invasive multi-cancer screenings.
~99.9% Negative Predictive Value (NPV): A negative result provides high confidence that no detectable cancer signal was present at the time of the test.
~58% Positive Predictive Value (PPV): On average, 2 to 3 out of 5 people with a positive result will be confirmed to have a condition requiring clinical follow-up or diagnosis.
~84% Accuracy in Predicting Organ of Origin: AI algorithms precisely locate the potential source of the cancer, helping doctors plan targeted follow-up examinations.

10 Types of Cancer Screened by SPOT-MAS

The technology covers a comprehensive range of common and aggressive cancers:

Common Cancers: Breast, Lung, Liver & Bile Duct, Colorectal, and Gastric (Stomach) cancer.
Aggressive & Hard-to-Detect Cancers: Oesophageal, Pancreatic, Ovarian, Endometrial, and certain Head & Neck cancers.
Limitations: This test does not include brain, thyroid, or certain skin cancers due to biological limitations in ctDNA shedding.

Understanding Your Results and Next Steps

SPOT-MAS is a screening tool for risk assessment and does not constitute a definitive medical diagnosis. Results are categorised into two main groups:

1. Negative Result

Meaning: No detectable ctDNA signals for the 10 specified cancers were found at the time of testing.
Important Note: A negative result does not 100% guarantee the absence of cancer or future cancer development.
Recommendation: Continue with regular annual health check-ups and standard age-appropriate screenings (e.g., Mammograms or Colonoscopies).

2. Positive Result

Meaning: Abnormal ctDNA signals were detected, indicating a risk of cancer in at least one organ. The AI will predict the most likely organ of origin.
Important Note: A positive result is not an immediate diagnosis of cancer.
Clinical Pathway:
1. Consult with a specialist at BNH Hospital for a detailed explanation.
2. Undergo targeted diagnostic imaging (e.g., CT scan, MRI, Endoscopy, or Ultrasound) based on the predicted location.
3. If a lesion is found, a biopsy may be recommended for definitive confirmation.
4. If no abnormality is immediately visible, a follow-up SPOT-MAS test in 6 months may be advised.

Frequently Asked Questions (FAQ)

Q: Is any special preparation required before the test?

A: No. The test requires a simple 10ml blood draw. Fasting (avoiding food and water) is not necessary before the procedure.

Q: Can SPOT-MAS replace standard cancer screenings?

A: No. SPOT-MAS is a "supplementary" proactive screening tool. It should be used alongside, not instead of, standard screenings like Pap smears, Mammograms, or Colonoscopies.

Q: Who should consider the SPOT-MAS test?

A: It is ideal for individuals aged 40 and above, those with a family history of cancer, or anyone seeking an advanced, non-invasive proactive health assessment.

BNH GiftAway 2025 SPOT-MAS (Genetic Screening for 10 Types of Cancer)

Special price Original price was: ฿24,520.

The price includes the doctor’s interpretation fee and hospital service charges, but excludes any additional expenses that may arise from further diagnostic examinations or treatments if abnormalities are detected.
The hospital reserves the right to amend the programme price as appropriate without prior notice.